Literature DB >> 1409740

Down syndrome and Alzheimer disease.

B T Hyman1.   

Abstract

The brains of individuals with Down's syndrome in their 40's and 50's begin to develop changes that are otherwise seen only in patients with Alzheimer disease. Neurons develop neurofibrillary tangles, flame-shaped alterations composed mainly of condensed cytoskeletal proteins. Another protein, beta/A4 amyloid, is deposited in large amounts in the form of senile plaques and, around blood vessels, amyloid angiopathy. With increasing age, Down syndrome individuals accumulate more and more of these changes. Different parts of the brain are affected to varying degrees by these two alterations. Surprisingly, the pattern of accumulation of neurofibrillary tangles and senile plaques is characteristic, and follows a predictable pattern. We have characterized this pattern in the hippocampal formation in a group of Down individuals, ages 13-71. Certain specific neurons such as those in layer II of entorhinal cortex and the CA1/subiculum field of the hippocampus are exquisitely vulnerable to tangle formation, and are the first neurons to be affected. Perhaps 20-30 years pass as the disease process evolves from mild to severe pathological changes. One hypothesis for why Down individuals would be predisposed to developing Alzheimer pathology is the observation that the gene that encodes the precursor of the amyloid protein is located on chromosome 21. An extra copy of this gene, such as occurs in Down syndrome, may lead to "overproduction" of amyloid, and ultimately to its accumulation as senile plaques. Experiments to test this hypothesis are now underway.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1409740

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  8 in total

1.  Does ceruloplasmin differential express in the brain of Ts65Dn: a mouse mode of Down syndrome?

Authors:  Bin Yu; Jing Kong; Baoling Xing; Ziqiang Zhu; Bin Zhang; Qiu-Wei Wang; Shi-He Shao
Journal:  Neurol Sci       Date:  2013-11-17       Impact factor: 3.307

2.  Life-long overexpression of S100beta in Down's syndrome: implications for Alzheimer pathogenesis.

Authors:  W S Griffin; J G Sheng; J E McKenzie; M C Royston; S M Gentleman; R A Brumback; L C Cork; M R Del Bigio; G W Roberts; R E Mrak
Journal:  Neurobiol Aging       Date:  1998 Sep-Oct       Impact factor: 4.673

3.  Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.

Authors:  William J Netzer; Craig Powell; Yi Nong; Jacqueline Blundell; Lili Wong; Karen Duff; Marc Flajolet; Paul Greengard
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

4.  Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B.

Authors:  Benjamin L Handen; Ann D Cohen; Umapathy Channamalappa; Peter Bulova; Sheila A Cannon; William I Cohen; Chester A Mathis; Julie C Price; William E Klunk
Journal:  Alzheimers Dement       Date:  2012-11       Impact factor: 21.566

5.  Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome.

Authors:  Nicole Schupf; Bindu Patel; Deborah Pang; Warren B Zigman; Wayne Silverman; Pankaj D Mehta; Richard Mayeux
Journal:  Arch Neurol       Date:  2007-07

6.  The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.

Authors:  David E Kang; Seung Eon Roh; Jung A Woo; Tian Liu; Jung Hyun Bu; A-Rong Jung; Yeory Lim
Journal:  Exp Neurobiol       Date:  2011-06-30       Impact factor: 3.261

7.  Bioinformatics characterization of differential proteins in serum of mothers carrying Down syndrome fetuses: combining bioinformatics and ELISA.

Authors:  Bin Yu; Bin Zhang; Ye Shi; Shi-He Shao; Qiu-Wei Wang; Rui-Ping Huang; Yu-Qi Yang
Journal:  Arch Med Sci       Date:  2012-05-09       Impact factor: 3.318

8.  Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.

Authors:  Xu-Qiao Chen; Ahmad Salehi; Matthew L Pearn; Cassia Overk; Phuong D Nguyen; Alexander M Kleschevnikov; Maria Maccecchini; William C Mobley
Journal:  Alzheimers Dement       Date:  2020-09-25       Impact factor: 21.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.